Hütter-Krönke ML, Fiedler W, Kündgen A, Krauter J, von Lilienfeld-Toal M, Döhner H, Schlenk RF. Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study. Haematologica [Internet]. 2019Jan.31 [cited 2026Nov.11];104(2):e63-e64. Available from: https://haematologica.org/article/view/8788